Cargando…

Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice

Tau protein aggregations are important contributors to the etiology of Alzheimer’s disease (AD). Hydromethylthionine (HMT) is a potent inhibitor of tau aggregation in vitro and in vivo and is being developed as a possible anti-dementia medication. HMT was also shown to affect the cholinergic system...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kondak, Constantin, Leith, Michael, Baddeley, Thomas C., Santos, Renato X., Harrington, Charles R., Wischik, Claude M., Riedel, Gernot, Klein, Jochen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341988/ https://www.ncbi.nlm.nih.gov/pubmed/37445987 http://dx.doi.org/10.3390/ijms241310810

Ejemplares similares

Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks
por: Schwab, Karima, et al.
Publicado: (2021)

HMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine
por: Santos, Renato X., et al.
Publicado: (2022)

Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model
por: Riedel, Gernot, et al.
Publicado: (2020)

Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease
por: Schelter, Bjoern O., et al.
Publicado: (2019)

Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia
por: Shiells, Helen, et al.
Publicado: (2020)

Exploring the Anti-Hypoxaemia Effect of Hydromethylthionine: A Prospective Study of Phase 3 Clinical Trial Participants
por: Arastoo, Mohammad, et al.
Publicado: (2023)

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
por: Wischik, Claude M., et al.
Publicado: (2022)

Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier
por: Bentham, Peter, et al.
Publicado: (2021)

Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer’s disease and frontotemporal lobar degeneration
por: Cranston, Anna L, et al.
Publicado: (2020)

Hypoxic and Hypercapnic Responses in Transgenic Murine Model of Alzheimer’s Disease Overexpressing Human AβPP: The Effects of Pretreatment with Memantine and Rivastigmine
por: Andrzejewski, Kryspin, et al.
Publicado: (2022)

Effects of rivastigmine and memantine alone and in combination on learning and memory in rats with scopolamine-induced amnesia
por: Yanev, Peter Georgiev, et al.
Publicado: (2015)

A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy
por: Schwab, Karima, et al.
Publicado: (2018)

Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia
por: Lemke, Nora, et al.
Publicado: (2021)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
por: Li, Dan-Dan, et al.
Publicado: (2019)

Modeling Prion-Like Processing of Tau Protein in Alzheimer’s Disease for Pharmaceutical Development
por: Wischik, Claude M., et al.
Publicado: (2018)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease
por: Lai, Robert Y. K., et al.
Publicado: (2016)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
por: Oakley, Sebastian S., et al.
Publicado: (2020)

Erratum: Lai, R.Y.K.; Harrington, C.R.; Wischik, C.M. Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease. Biomolecules 2016, 6, 19
por: Lai, Robert Y. K., et al.
Publicado: (2016)

Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models
por: Melis, Valeria, et al.
Publicado: (2015)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
por: dos Santos, Gustavo Alves Andrade, et al.
Publicado: (2011)

Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s Disease
por: Arastoo, Mohammad, et al.
Publicado: (2020)

Solid-state NMR of paired helical filaments formed by the core tau fragment tau(297-391)
por: Al-Hilaly, Youssra K., et al.
Publicado: (2022)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

Acquired Localized Hypertrichosis Induced by Rivastigmine
por: Imbernón-Moya, Adrian, et al.
Publicado: (2016)

Memantine ameliorates oxaliplatin-induced neurotoxicity via mitochondrial protection
por: Wang, Youyu, et al.
Publicado: (2022)

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011)

Rivastigmine for the treatment of dementia associated with Parkinson’s disease
por: Reingold, Jennifer L, et al.
Publicado: (2007)

Rivastigmine in Chinese patients with subcortical vascular dementia
por: Mok, Vincent, et al.
Publicado: (2007)

Effects of rivastigmin tartarat in the therapy of patients with schizophrenia
por: Djordjevic, Snezana, et al.
Publicado: (2010)

Direct Asymmetric Reductive Amination for the Synthesis of (S)-Rivastigmine
por: Gao, Guorui, et al.
Publicado: (2018)

Treatment of pediatric antimuscarinic delirium with oral rivastigmine
por: Yakey, Brandtly, et al.
Publicado: (2023)

Oxidative Stress Conditions Result in Trapping of PHF-Core Tau (297–391) Intermediates
por: Maina, Mahmoud B., et al.
Publicado: (2021)

Memantine Differentially Regulates Tau Phosphorylation Induced by Chronic Restraint Stress of Varying Duration in Mice
por: Liu, Yunsheng, et al.
Publicado: (2019)

Oral Administration of Memantine Prolongs Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
por: Joo, In-Soo, et al.
Publicado: (2007)

Paired Helical Filament-Forming Region of Tau (297–391) Influences Endogenous Tau Protein and Accumulates in Acidic Compartments in Human Neuronal Cells
por: Pollack, Saskia J., et al.
Publicado: (2020)

Pharmacodynamics of Memantine: An Update
por: Rammes, G, et al.
Publicado: (2008)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_v92d7ih927gdr1rqusc9vc1fi1